Response to 'Hydrocortisone suspension formulations are not necessarily the same in the treatment of children with congenital adrenal hyperplasia'
Eur J Endocrinol
.
2020 Dec;183(6):L29-L30.
doi: 10.1530/EJE-20-1047.
Authors
Robin Michelet
1
,
Johanna Melin
1
2
,
Zinnia P Parra-Guillen
1
3
,
Uta Neumann
4
,
Martin J Whitaker
5
,
Viktoria Stachanow
1
2
,
Wilhelm Huisinga
6
,
John Porter
5
,
Oliver Blankenstein
4
,
Richard J Ross
7
,
Charlotte Kloft
1
Affiliations
1
Department of Clinical Pharmacy and Biochemistry, Institute of Pharmacy, Freie Universitaet Berlin, Berlin, Germany.
2
Graduate Research Training Program, PharMetrX, Berlin, Germany.
3
Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, Universidad de Navarra, Pamplona, Spain.
4
Charité-Universitätsmedizin, Berlin, Germany.
5
Diurnal Limited, Cardiff, UK.
6
Institute of Mathematics, Universität Potsdam, Germany.
7
University of Sheffield, Sheffield, UK.
PMID:
33105103
DOI:
10.1530/EJE-20-1047
No abstract available
Publication types
Comment
MeSH terms
Adrenal Hyperplasia, Congenital* / drug therapy
Child
Drug Compounding
Humans
Hydrocortisone*
Substances
Hydrocortisone